Combining Azacitidine/Enasidenib to Enhance the Treatment of Newly Diagnosed IDH2-Mutant AML
Courtney D. DiNardo, MD, MSCE, explains the rationale for the phase II AG221-AML-005 trial.
Courtney D. DiNardo, MD, MSCE, an assistant professor in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, explains the rationale for the phase II AG221-AML-005 trial.
For the older population of patients with acute myeloid leukemia (AML), the current standard of care in the United States is azacitidine (Vidaza). The drug can lead to a complete remission rate of about 20%, an overall response rate of about 30%, and overall survival of around 12 months, says DiNardo.
The IDH2 inhibitor enasidenib (Idhifa) has been approved for the treatment of relapsed/refractoryIDH2-mutated AML, and it’s promising activity in this patient population raised the question of whether patients who were newly diagnosed withIDH2-mutant AML could derive benefit from enasidenib in combination with azacitidine.
For more on the AG221-AML-005 trial:https://www.targetedonc.com/news/enasidenib-plus-azacitidine-expands-treatment-landscape-for-idh2mutant-aml
Targeted Therapies Continue to Push the Field of EGFRm Lung Cancer Forward
December 6th 2023In an interview with Targeted Oncology, Edward B. Garon, MD, MS, discussed the ever-changing treatment landscape for EGFR-mutated lung cancer, as well as the unmet needs and potential next steps for research in this space.
Read More
FDA Clears IND for CT071 in RRMM and Primary Plasma Cell Leukemia
December 5th 2023CT071, a chimeric antigen receptor T-cell therapy candidate, had an investigational new drug application cleared by the FDA for patients with relapsed/refractory multiple myeloma and primary plasma cell leukemia.
Read More
Connecting Heart Disease and Hematologic Malignancies
November 28th 2023A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.
Read More
